ANBICYN POWDER FOR INJECTION

AU:B1 J01CR(WHO) (combinations withpenicillins) AU:S4(Prescription only)In general: ℞ (Prescription only) (2R,5R,Z)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid 58001-44-8Y 5280980 DB00766Y 4444466Y 23521W1S24 D07711Y CHEBI:48947Y ChEMBL777Y DTXSID2022830 Interactive image O=C2N1[C@H](C(/O[C@@H]1C2)=C/CO)C(=O)O InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1YKey:HZZVJAQRINQKSD-PBFISZAISA-NY Clavulanic acidis aβ-lactam drugthat functions as amechanism-basedβ-lactamase inhibitor. While not effective by itself as anantibiotic, when combined withpenicillin-group antibiotics, it can overcomeantibiotic resistanceinbacteriathat secreteβ-lactamase, which otherwise inactivates most penicillins. In its most common preparations, potassium clavulanate (clavulanic acid as a salt of potassium) is combined with: amoxicillin(co-amoxiclav, trade names Augmentin, Clavulin, Tyclav, Clavaseptin (veterinary), Clavamox (veterinary), Synulox (veterinary), and others)ticarcillin(co-ticarclav, trade name Timentin) Clavulanic acid was patented in 1974.In addition to its β-lactamase inhibition, clavulanic acid showsoff-target activityin thenervous systemby upregulating theglutamate transporter 1(GLT-1) and has been studied in the potential treatment of a variety ofcentral nervous systemdisorders.